Given the reduced importance of CXCR4/CXCL12 in CML compared with normal HSCs, and CXCR4 antagonists are potential therapeutics for treatment of CML, the particular application that captures our attention is the recurrence of active leukemia. The gene discussed is CXCL12; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.